After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant ...

The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...

Federal agencies must stop disbursing financial assistance under a new budget directive, threatening funding for providers ...